Lisata Therapeutics Inc. (LSTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lisata Therapeutics Inc. (LSTA) has a cash flow conversion efficiency ratio of -0.195x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.34 Million) by net assets ($17.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Lisata Therapeutics Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Lisata Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (1993–2024)
This chart illustrates how Lisata Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lisata Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lisata Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ram Technology Co. Ltd
KQ:171010
|
-0.015x |
|
Systech Bhd
KLSE:0050
|
1.187x |
|
TINYBUILD REGSCAT3 DL-001
F:8Z3
|
N/A |
|
Union Community Co. Ltd
KQ:203450
|
-0.018x |
|
Yoo Sung Ent
KO:002920
|
0.030x |
|
Drax Group PLC
LSE:DRX
|
0.144x |
|
Future Battery Minerals Ltd
AU:FBM
|
-0.035x |
|
FSBM Holdings Bhd
KLSE:9377
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Lisata Therapeutics Inc. (1993–2024)
The table below shows the annual cash flow conversion efficiency of Lisata Therapeutics Inc. from 1993 to 2024. For the full company profile with market capitalisation and key ratios, see Lisata Therapeutics Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $29.32 Million | $-19.36 Million | -0.660x | -57.85% |
| 2023-12-31 | $47.89 Million | $-20.03 Million | -0.418x | -31.04% |
| 2022-12-31 | $66.32 Million | $-21.17 Million | -0.319x | -32.01% |
| 2021-12-31 | $92.00 Million | $-22.25 Million | -0.242x | +11.64% |
| 2020-12-31 | $32.24 Million | $-8.82 Million | -0.274x | +70.21% |
| 2019-12-31 | $20.55 Million | $-18.88 Million | -0.919x | -72.17% |
| 2018-12-31 | $37.45 Million | $-19.99 Million | -0.534x | -28.29% |
| 2017-12-31 | $50.19 Million | $-20.88 Million | -0.416x | +92.85% |
| 2016-12-31 | $4.07 Million | $-23.67 Million | -5.820x | -245.19% |
| 2015-12-31 | $23.28 Million | $-39.26 Million | -1.686x | -108.80% |
| 2014-12-31 | $58.07 Million | $-46.90 Million | -0.808x | -84.81% |
| 2013-12-31 | $62.03 Million | $-27.10 Million | -0.437x | -3.52% |
| 2012-12-31 | $32.82 Million | $-13.85 Million | -0.422x | -61.61% |
| 2011-12-31 | $80.13 Million | $-20.93 Million | -0.261x | -166.47% |
| 2010-12-31 | $86.49 Million | $-8.48 Million | -0.098x | +32.47% |
| 2009-12-31 | $59.59 Million | $-8.65 Million | -0.145x | +97.35% |
| 2008-12-31 | $863.18K | $-4.73 Million | -5.482x | -196.46% |
| 2007-12-31 | $3.32 Million | $-6.13 Million | -1.849x | +85.16% |
| 2006-12-31 | $292.11K | $-3.64 Million | -12.457x | -2814.98% |
| 2005-12-31 | $-1.82 Million | $-834.00K | 0.459x | -39.28% |
| 2004-12-31 | $-1.93 Million | $-1.46 Million | 0.756x | +11.11% |
| 2003-12-31 | $-1.50 Million | $-1.02 Million | 0.680x | +155.73% |
| 2002-12-31 | $-823.89K | $1.01 Million | -1.220x | -21.99% |
| 2001-12-31 | $373.73K | $-373.84K | -1.000x | -58.51% |
| 2000-12-31 | $3.13 Million | $-1.98 Million | -0.631x | -579.82% |
| 1999-12-31 | $3.92 Million | $-364.12K | -0.093x | -110.60% |
| 1998-12-31 | $-307.81K | $-269.60K | 0.876x | +87.60% |
| 1996-12-31 | $-651.71K | $-304.27K | 0.467x | -82.23% |
| 1995-12-31 | $-319.11K | $-838.44K | 2.627x | +807.11% |
| 1994-12-31 | $-2.90 Million | $-840.00K | 0.290x | -- |
| 1993-12-31 | $0.00 | $470.00K | x | -- |
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more